Braish, J., Ali, N. A., Komrokji, Z., Xie, Z., Chan, O., Kuykendall, A., Yun, S., Shallis, R., Reynolds, S., Walker, A., Lancet, J., Padron, E., Sallman, D., Komrokji, R. (2025). Durability of complete response outperforms complete response rates as a surrogate endpoint for advancing to phase III trials in high-risk myelodysplastic syndromes. Blood. https://doi.org/10.1182/blood-2025-240